source
- Pfizer sells Seagen-derived ADC to Medicus Pharma for $12 million upfront, potential $1 billion milestonesPfizer has transferred rights to an antibody‑drug conjugate it acquired in its Seagen purchase to Medicus Pharma. Medicus will pay $12 million upfront and $15 million a year later, and Pfizer coul…
- GSK licenses Hutchmed's KRAS-EGFR antibody-drug conjugate for $110 million upfrontGSK announced it will pay $110 million upfront to obtain a license for a KRAS-EGFR antibody-drug conjugate developed by Chinese biopharma Hutchmed. The agreement also includes potential milestone p…